{"entity":{"type":"insider","cik":"0001603347","url":"/insider/0001603347","json_url":"/insider/0001603347.json","name":"Huizenga Theodore Alan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":39,"n_filings":34,"first":"2015-06-19","last":"2026-03-03","span_basis":"filed_date"},"name_variants":[{"name":"Huizenga Theodore Alan","source":"filing","n_filings":34,"first_seen":"2015-06-19","last_seen":"2026-03-03"}],"transactions":[{"id":5958823,"accession":"0001193125-26-089109","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-089109","line_url":"/filing/0001193125-26-089109#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1632.0,"shares_display":"1,632","price_per_share":22.8,"price_display":"22.80","price_state":"stated","total_value":37209.6,"total_display":"37,209.60","total_whole":"37,210","shares_owned_after":48670.0,"shares_owned_after_display":"48,670","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-03","scope":"insider"},{"id":4673287,"accession":"0001193125-25-336619","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-336619","line_url":"/filing/0001193125-25-336619#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":85.0,"shares_display":"85","price_per_share":34.38,"price_display":"34.38","price_state":"stated","total_value":2922.3,"total_display":"2,922.30","total_whole":"2,922","shares_owned_after":50450.0,"shares_owned_after_display":"50,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-29","filed_date":"2025-12-30","scope":"insider"},{"id":4372100,"accession":"0001193125-25-209387","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-209387","line_url":"/filing/0001193125-25-209387#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64.0,"shares_display":"64","price_per_share":29.17,"price_display":"29.17","price_state":"stated","total_value":1866.88,"total_display":"1,866.88","total_whole":"1,867","shares_owned_after":50242.0,"shares_owned_after_display":"50,242","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-18","filed_date":"2025-09-19","scope":"insider"},{"id":4342203,"accession":"0000950170-25-113446","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-113446","line_url":"/filing/0000950170-25-113446#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":84.0,"shares_display":"84","price_per_share":31.39,"price_display":"31.39","price_state":"stated","total_value":2636.76,"total_display":"2,636.76","total_whole":"2,637","shares_owned_after":50306.0,"shares_owned_after_display":"50,306","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-05","filed_date":"2025-09-08","scope":"insider"},{"id":4660129,"accession":"0000950170-25-032764","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-032764","line_url":"/filing/0000950170-25-032764#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":967.0,"shares_display":"967","price_per_share":42.1,"price_display":"42.10","price_state":"stated","total_value":40710.7,"total_display":"40,710.70","total_whole":"40,711","shares_owned_after":50265.0,"shares_owned_after_display":"50,265","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-04","scope":"insider"},{"id":2638440,"accession":"0000950170-24-103807","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-103807","line_url":"/filing/0000950170-24-103807#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":91.0,"shares_display":"91","price_per_share":56.19,"price_display":"56.19","price_state":"stated","total_value":5113.29,"total_display":"5,113.29","total_whole":"5,113","shares_owned_after":41551.0,"shares_owned_after_display":"41,551","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-03","filed_date":"2024-09-05","scope":"insider"},{"id":2235414,"accession":"0000950170-24-026641","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-026641","line_url":"/filing/0000950170-24-026641#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":341.0,"shares_display":"341","price_per_share":53.76,"price_display":"53.76","price_state":"stated","total_value":18332.16,"total_display":"18,332.16","total_whole":"18,332","shares_owned_after":41380.0,"shares_owned_after_display":"41,380","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-01","filed_date":"2024-03-05","scope":"insider"},{"id":8023318,"accession":"0001209191-23-048905","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-048905","line_url":"/filing/0001209191-23-048905","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2163.0,"shares_display":"2,163","price_per_share":40.79954692556635,"price_display":"40.80","price_state":"stated","total_value":88249.42,"total_display":"88,249.42","total_whole":"88,249","shares_owned_after":23777.0,"shares_owned_after_display":"23,777","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-07","filed_date":"2023-09-11","scope":"insider","n_lines":2},{"id":8726786,"accession":"0001209191-23-048489","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-048489","line_url":"/filing/0001209191-23-048489","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":970.0,"shares_display":"970","price_per_share":37.146731958762885,"price_display":"37.15","price_state":"stated","total_value":36032.33,"total_display":"36,032.33","total_whole":"36,032","shares_owned_after":23864.0,"shares_owned_after_display":"23,864","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-01","filed_date":"2023-09-06","scope":"insider","n_lines":2},{"id":8106067,"accession":"0001209191-23-016045","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-016045","line_url":"/filing/0001209191-23-016045#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":45.65,"price_display":"45.65","price_state":"stated","total_value":4565.0,"total_display":"4,565.00","total_whole":"4,565","shares_owned_after":23048.0,"shares_owned_after_display":"23,048","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider"},{"id":8392028,"accession":"0001209191-23-014502","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-014502","line_url":"/filing/0001209191-23-014502#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":639.0,"shares_display":"639","price_per_share":43.4,"price_display":"43.40","price_state":"stated","total_value":27732.6,"total_display":"27,732.60","total_whole":"27,733","shares_owned_after":15558.0,"shares_owned_after_display":"15,558","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-28","filed_date":"2023-03-02","scope":"insider"},{"id":6193343,"accession":"0001209191-22-062400","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-062400","line_url":"/filing/0001209191-22-062400#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2031.0,"shares_display":"2,031","price_per_share":43.96,"price_display":"43.96","price_state":"stated","total_value":89282.76,"total_display":"89,282.76","total_whole":"89,283","shares_owned_after":16197.0,"shares_owned_after_display":"16,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-21","filed_date":"2022-12-22","scope":"insider"},{"id":6608144,"accession":"0001209191-22-024699","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-024699","line_url":"/filing/0001209191-22-024699#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":132.0,"shares_display":"132","price_per_share":84.55,"price_display":"84.55","price_state":"stated","total_value":11160.6,"total_display":"11,160.60","total_whole":"11,161","shares_owned_after":16914.0,"shares_owned_after_display":"16,914","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-16","filed_date":"2022-04-19","scope":"insider"},{"id":6890361,"accession":"0001209191-22-015819","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-015819","line_url":"/filing/0001209191-22-015819#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":843.0,"shares_display":"843","price_per_share":66.62,"price_display":"66.62","price_state":"stated","total_value":56160.66,"total_display":"56,160.66","total_whole":"56,161","shares_owned_after":13229.0,"shares_owned_after_display":"13,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-03","scope":"insider"},{"id":4956776,"accession":"0001209191-21-060756","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-060756","line_url":"/filing/0001209191-21-060756#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":140.0,"shares_display":"140","price_per_share":81.14,"price_display":"81.14","price_state":"stated","total_value":11359.6,"total_display":"11,359.60","total_whole":"11,360","shares_owned_after":14072.0,"shares_owned_after_display":"14,072","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-14","filed_date":"2021-10-18","scope":"insider"},{"id":5043836,"accession":"0001209191-21-031386","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-031386","line_url":"/filing/0001209191-21-031386#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":142.0,"shares_display":"142","price_per_share":113.67,"price_display":"113.67","price_state":"stated","total_value":16141.14,"total_display":"16,141.14","total_whole":"16,141","shares_owned_after":15031.0,"shares_owned_after_display":"15,031","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-06","filed_date":"2021-05-10","scope":"insider"},{"id":4775362,"accession":"0001209191-21-018872","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-018872","line_url":"/filing/0001209191-21-018872#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":120.69,"price_display":"120.69","price_state":"stated","total_value":362070.0,"total_display":"362,070.00","total_whole":"362,070","shares_owned_after":13544.0,"shares_owned_after_display":"13,544","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-08","filed_date":"2021-03-09","scope":"insider"},{"id":4417361,"accession":"0001209191-21-017556","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-017556","line_url":"/filing/0001209191-21-017556#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":732.0,"shares_display":"732","price_per_share":138.17,"price_display":"138.17","price_state":"stated","total_value":101140.44,"total_display":"101,140.44","total_whole":"101,140","shares_owned_after":16544.0,"shares_owned_after_display":"16,544","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-03","scope":"insider"},{"id":5034263,"accession":"0001209191-21-002825","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-002825","line_url":"/filing/0001209191-21-002825#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":140.65,"price_display":"140.65","price_state":"stated","total_value":562600.0,"total_display":"562,600.00","total_whole":"562,600","shares_owned_after":15716.0,"shares_owned_after_display":"15,716","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-07","filed_date":"2021-01-08","scope":"insider"},{"id":2192338,"accession":"0001209191-20-055173","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-055173","line_url":"/filing/0001209191-20-055173#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":146.0,"shares_display":"146","price_per_share":87.98,"price_display":"87.98","price_state":"stated","total_value":12845.08,"total_display":"12,845.08","total_whole":"12,845","shares_owned_after":16436.0,"shares_owned_after_display":"16,436","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-14","filed_date":"2020-10-16","scope":"insider"},{"id":2338781,"accession":"0001209191-20-042195","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-042195","line_url":"/filing/0001209191-20-042195","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2638.0,"shares_display":"2,638","price_per_share":91.0,"price_display":"91.00","price_state":"stated","total_value":240058.0,"total_display":"240,058.00","total_whole":"240,058","shares_owned_after":16582.0,"shares_owned_after_display":"16,582","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-07-08","filed_date":"2020-07-10","scope":"insider","n_lines":2},{"id":3115593,"accession":"0001209191-20-040944","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-040944","line_url":"/filing/0001209191-20-040944","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2611.0,"shares_display":"2,611","price_per_share":81.0,"price_display":"81.00","price_state":"stated","total_value":211491.0,"total_display":"211,491.00","total_whole":"211,491","shares_owned_after":17220.0,"shares_owned_after_display":"17,220","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-07-01","filed_date":"2020-07-06","scope":"insider","n_lines":2},{"id":2682789,"accession":"0001209191-20-032267","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-032267","line_url":"/filing/0001209191-20-032267#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":260.0,"shares_display":"260","price_per_share":74.93,"price_display":"74.93","price_state":"stated","total_value":19481.8,"total_display":"19,481.80","total_whole":"19,482","shares_owned_after":18331.0,"shares_owned_after_display":"18,331","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-26","filed_date":"2020-05-27","scope":"insider"},{"id":3197774,"accession":"0001209191-20-030710","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-030710","line_url":"/filing/0001209191-20-030710","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2461.0,"shares_display":"2,461","price_per_share":71.0,"price_display":"71.00","price_state":"stated","total_value":174731.0,"total_display":"174,731.00","total_whole":"174,731","shares_owned_after":19024.0,"shares_owned_after_display":"19,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-15","filed_date":"2020-05-19","scope":"insider","n_lines":2},{"id":3253314,"accession":"0001209191-20-003425","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-003425","line_url":"/filing/0001209191-20-003425#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (SVP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (SVP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":61.0,"price_display":"61.00","price_state":"stated","total_value":61000.0,"total_display":"61,000.00","total_whole":"61,000","shares_owned_after":15946.0,"shares_owned_after_display":"15,946","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-14","filed_date":"2020-01-15","scope":"insider"},{"id":9270857,"accession":"0001209191-19-025117","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-025117","line_url":"/filing/0001209191-19-025117#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (VP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (VP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":254.0,"shares_display":"254","price_per_share":65.52,"price_display":"65.52","price_state":"stated","total_value":16642.08,"total_display":"16,642.08","total_whole":"16,642","shares_owned_after":15642.0,"shares_owned_after_display":"15,642","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-05","filed_date":"2019-04-17","scope":"insider"},{"id":6101271,"accession":"0001209191-18-038210","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-038210","line_url":"/filing/0001209191-18-038210#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (VP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (VP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":955.0,"shares_display":"955","price_per_share":83.7,"price_display":"83.70","price_state":"stated","total_value":79933.5,"total_display":"79,933.50","total_whole":"79,934","shares_owned_after":11940.0,"shares_owned_after_display":"11,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-15","filed_date":"2018-06-15","scope":"insider"},{"id":6017131,"accession":"0001209191-18-037560","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-037560","line_url":"/filing/0001209191-18-037560#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (VP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (VP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1338.0,"shares_display":"1,338","price_per_share":76.97,"price_display":"76.97","price_state":"stated","total_value":102985.86,"total_display":"102,985.86","total_whole":"102,986","shares_owned_after":9940.0,"shares_owned_after_display":"9,940","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-13","filed_date":"2018-06-13","scope":"insider"},{"id":4223380,"accession":"0001209191-17-036024","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-036024","line_url":"/filing/0001209191-17-036024#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (VP, Controller and PAO)","role_mark":"O","role_mark_label":"Officer (VP, Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":480.0,"shares_display":"480","price_per_share":57.46,"price_display":"57.46","price_state":"stated","total_value":27580.8,"total_display":"27,580.80","total_whole":"27,581","shares_owned_after":9366.0,"shares_owned_after_display":"9,366","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-26","filed_date":"2017-05-26","scope":"insider"},{"id":5279559,"accession":"0001209191-17-019902","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-019902","line_url":"/filing/0001209191-17-019902#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (Controller and PAO)","role_mark":"O","role_mark_label":"Officer (Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":86.338,"price_display":"86.34","price_state":"stated","total_value":215845.0,"total_display":"215,845.00","total_whole":"215,845","shares_owned_after":9709.0,"shares_owned_after_display":"9,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-09","filed_date":"2017-03-10","scope":"insider"},{"id":2877073,"accession":"0001562180-16-003581","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-16-003581","line_url":"/filing/0001562180-16-003581#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (Controller and PAO)","role_mark":"O","role_mark_label":"Officer (Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":79.73,"price_display":"79.73","price_state":"stated","total_value":159460.0,"total_display":"159,460.00","total_whole":"159,460","shares_owned_after":11134.0,"shares_owned_after_display":"11,134","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-16","filed_date":"2016-11-18","scope":"insider"},{"id":8112565,"accession":"0001562180-15-001107","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-15-001107","line_url":"/filing/0001562180-15-001107#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (Controller and PAO)","role_mark":"O","role_mark_label":"Officer (Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":110.55,"price_display":"110.55","price_state":"stated","total_value":165825.0,"total_display":"165,825.00","total_whole":"165,825","shares_owned_after":2500.0,"shares_owned_after_display":"2,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-18","filed_date":"2015-12-18","scope":"insider"},{"id":8222721,"accession":"0001562180-15-000507","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-15-000507","line_url":"/filing/0001562180-15-000507#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (Controller and PAO)","role_mark":"O","role_mark_label":"Officer (Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":94.8,"price_display":"94.80","price_state":"stated","total_value":142200.0,"total_display":"142,200.00","total_whole":"142,200","shares_owned_after":2500.0,"shares_owned_after_display":"2,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-17","filed_date":"2015-06-19","scope":"insider"},{"id":2189576,"accession":"0001562180-16-003577","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-16-003577","line_url":"/filing/0001562180-16-003577#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001603347","owner_name":"Huizenga Theodore Alan","owner_display_name":"Huizenga Theodore Alan","owner_url":"/insider/0001603347","role":"Officer (Controller and PAO)","role_mark":"O","role_mark_label":"Officer (Controller and PAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Controller and PAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":94.8,"price_display":"94.80","price_state":"stated","total_value":142200.0,"total_display":"142,200.00","total_whole":"142,200","shares_owned_after":4300.0,"shares_owned_after_display":"4,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-17","filed_date":"2016-11-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":39,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":39,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":39},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Officer (SVP, Chief Accounting Officer)","n_filings":34,"first_seen":"2015-06-19","last_seen":"2026-03-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001603347","retrieved_at":"2026-08-23T06:17:42+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}